CTChristopher Daniel Tristan

Christopher Daniel Tristan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christopher Daniel Tristan has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic Performance of Micro-RNAs as Biomarkers for Endometrial Cancer: A Systematic Review and Meta-Analysis

    by Andi Darma Putra, Aldi Tamara Rahman, Lasmini Syariatin, Naufal Syafiq Darmawan, Kevin Nathaniel Cuandra, Muhammad Farid Hamka, Daivan Febri Juan Setiya, Aqilah Nurahmah Argani, Zaki Sidqi Aaliyya Aaliyya, Vina Sari Nugrahaning Widi, et al.

    Background Endometrial cancer (EC) is a common gynecologic malignancy with a growing need for accurate, minimally invasive diagnostic biomarkers. MicroRNAs (miRNAs) are stable across multiple biological specimens and have emerged as promising diagnostic candidates. This meta-analysis evaluated the diagnostic performance of single-miRNA biomarkers and multi-miRNA panels for EC. Methods A systematic review and diagnostic test accuracy meta-analysis was conducted according to PRISMA 2020. PubMed/MEDLINE, Embase, Web of Science, and ScienceDirect were searched through August 2025. Only one diagnostic estimate per independent participant cohort was included within each co-primary analysis. Single-miRNA biomarkers and multi-miRNA panels were analyzed separately using bivariate random-effects models. Pooled sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio (DOR), and SROC AUC were estimated. Results Eleven articles were included. Eight independent estimates contributed to the single-miRNA analysis and five to the multi-miRNA panel analysis. Single miRNAs yielded a pooled sensitivity of 0.90 (95% CI 0.82–0.95), specificity of 0.87 (0.75–0.94), DOR of 59.96 (18.59–193.37), and AUC of 0.95 (0.92–0.96). Multi-miRNA panels showed a sensitivity of 0.92 (0.87–0.95), specificity of 0.95 (0.88–0.98), DOR of 212.96 (67.84–668.52), and AUC of 0.95 (0.93–0.97). Sensitivity analyses supported the overall robustness of the findings. Conclusions MiRNA-based biomarkers show promising diagnostic discrimination for EC, but current evidence remains insufficient for routine clinical implementation. Prospective multicenter validation with standardized assays and prespecified thresholds is required.

  • Leadless Pacemakers After Transcatheter Aortic Valve Replacement: A Meta‐analysis With Time‐to‐Event Analysis

    by Frengki Prabowo Saputro Wijayanto, Christopher Daniel Tristan, Muhammad Reva Aditya, Artha Maressa Theodora Simanjuntak, Raymond Pranata

    Background: Permanent pacemaker implantation is a common complication after transcatheter aortic valve replacement (TAVR). Leadless pacemakers (LPs) may reduce lead‐ and pocket‐related complications, but their clinical outcomes after TAVR remain uncertain. This systematic review and meta‐analysis evaluated the safety and effectiveness of LPs compared with transvenous pacemakers (TVPs). Methods: PubMed, Scopus, and ScienceDirect were searched from inception to June 10, 2026. Randomized and observational studies were included. Random‐effects meta‐analyses pooled proportions, risk ratios (RRs), and mean differences (MDs). Reconstructed Kaplan–Meier data were used to estimate hazard ratios (HRs). Results: Ten studies involving 10,809 patients (1030 LP and 9779 TVP recipients) were included. The pooled procedural success rate of LP implantation was 98% (95% CI 95%–99%). Implantation success was comparable between LP and TVP (RR 1.00, 95% CI 0.98–1.02). Sensitivity analysis demonstrated a shorter hospital stay with LP (MD −1.37 days, 95% CI −2.33 to −0.41) and a lower risk of heart failure hospitalization (RR 0.37, 95% CI 0.14–0.96). Overall survival did not differ between groups (HR 1.05, 95% CI 0.44–1.23), although reconstructed survival curves showed late separation favoring LP. Device‐related and vascular complications were comparable between LP and TVP. Conclusions: LP implantation after TAVR demonstrates excellent procedural success and clinical outcomes comparable to TVPs. LPs may reduce hospital stay and heart failure hospitalization, supporting their use as an alternative pacing strategy in appropriately selected patients.

  • Clinical applicability of artificial intelligence electrocardiogram interpretation in Brugada syndrome: a diagnostic accuracy meta-analysis

    by Kevin Nathaniel Cuandra, Christopher Daniel Tristan, Indah Kurnia Hutabarat, Vina Sari Nugrahaning Widi, Dwi Nurcahya Ananda Suwarya, Raymond Elbert Budianto, Delinda Ivania Zhavira Wibowo, Siti Faiza Aliya, Ayu Mas Eka Pradnyani, Dhyani Paramita Wahyudi, et al.

    1. Brugada syndrome (BrS) is a rare inherited cardiac sodium channelopathy associated with malignant ventricular arrhythmias and sudden cardiac death (SCD) in structurally normal hearts [1]. Althou...

  • Open Access

    Smoking and Risk of Atrial Fibrillation Recurrence After Catheter Ablation: A Meta‐Analysis and Meta‐Regression

    by Frengki Prabowo Saputro Wijayanto, Artha Maressa Theodora Simanjuntak, Muhammad Reva Aditya, Alifian Arkan Zaky Kusnadi, Alphatar Magnus Jonathan Tambunan, Harmony Tiffany Clay, Erlangga Dief Putra Hamam, Christopher Daniel Tristan, Raymond Pranata

    Background: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide. Although catheter ablation is an established rhythm‐control strategy, recurrence remains frequent. Smoking is a potentially modifiable risk factor, but its impact on post‐ablation AF recurrence remains uncertain. This study evaluated the association between smoking status and AF recurrence following catheter ablation. Method: Six databases were searched up to March 2026. Studies including patients with AF undergoing first‐time catheter ablation and reporting recurrence outcomes stratified by smoking status were included. Sensitivity, subgroup, and meta‐regression analyses were performed. Publication bias was evaluated using Egger's test and trim‐and‐fill analysis. Result: Twenty‐two studies comprising 6047 participants were included. Smoking was associated with a significantly increased risk of AF recurrence following catheter ablation (OR 1.42, 95% CI: 1.09–1.85; p = 0.0096), with substantial heterogeneity ( I 2 = 65.8%). Sensitivity analysis confirmed the robustness of the findings (OR 1.35, 95% CI: 1.05–1.73). No significant small‐study effects were detected (Egger's p = 0.4280), although trim‐and‐fill analysis attenuated the association to borderline significance. Meta‐regression identified body mass index (BMI) as a significant moderator, with a weaker association observed in populations with higher BMI. Conclusion: Smoking is associated with a modest but significant increase in the risk of AF recurrence after catheter ablation. Future studies should evaluate the impact of smoking intensity, duration, and cessation on ablation outcomes using patient‐level data.

  • Open Access

    Exploration of Compounds Identified from Amomum cardamomum Seed Extract: LC-MS Profiling, Network Pharmacology, and Computational Analyses for Innovative Multi-Targeted Breast Cancer Therapy

    by Dessy Arisanty, Salsabila Putri Khairani, Kevin Nathaniel Cuandra, Aldi Tamara Rahman, Christopher Daniel Tristan, Angela Stephanie Yahono, Muhammad Samudra Ilham, Ajib Zaim Alamsyah, Bezalel Tioleyson Sarjono, Daivan Febri Juan Setiya, et al.

    Background Breast cancer remains one of the leading causes of cancer-related mortality worldwide, and the emergence of drug resistance, systemic toxicity, and limited efficacy of current therapies highlight the need for safer and more effective treatment. Natural products have emerged as promising sources of multi-target anticancer agents. A. cardamomum has demonstrated preliminary anticancer potential, yet the bioactive constituents and their molecular mechanisms in breast cancer remain poorly elucidated. Methods This study integrated in silico approaches to investigate the therapeutic potential of A. cardamomum seed extract against breast cancer. LC–MS analysis identified phytochemical compounds, followed by network pharmacology to determine their potential targets and molecular pathways. Pharmacokinetic and toxicity predictions were assessed through ADMET and Lipinski’s rule of five analyses to evaluate drug-likeness and safety. Molecular docking and molecular dynamics (MD) simulations were conducted to evaluate binding affinity and structural stability of compounds with key oncogenic proteins. Results LC-MS profiling identified 22 distinct compounds in A. cardamomum seeds. ADMET and Lipinski analyses demonstrated that most compounds possessed high gastrointestinal absorption, favorable oral bioavailability, and low toxicity risk. Network pharmacology highlighting SRC, TNF-α, Caspase-3, and EGFR as central nodes in the protein-protein interaction network. Molecular docking identified compounds C17 and C20 as the most promising bioactives, showing strong binding affinities and interactions similar to control ligands. MD simulations confirmed their stable complexes, indicating conformational stability and robust ligand–protein interactions. Conclusion This study highlights the promising multi-target anticancer potential of A. cardamomum seeds. Compounds C17 and C20 were identified as lead candidates with strong and stable interactions with key breast cancer-related proteins and favorable pharmacokinetic properties. These results suggest that A. cardamomum could serve as a potential source for developing new plant-based therapies against breast cancer. Further in vitro and in vivo investigations are warranted to validate their efficacy and safety.

  • Open Access

    Early catheter ablation for atrial fibrillation after acute decompensated heart failure: a systematic review and meta-analysis with reconstructed Kaplan–Meier individual patient data

    by Raymond Pranata, Christopher Daniel Tristan, Emir Yonas, Artha Maressa Theodora Simanjuntak, Frengki Prabowo Saputro Wijayanto, Wilbert Huang, Antonia Anna Lukito


  • Open Access

    Giant bladder stone encrusting a forgotten migrated intrauterine device: a rare case report and review of the published data

    by Afifah Widyadhari, Видьядхари Афифа, Raden R. A. Wicaksono, Вичаксоно Раден Р. А., Ali Husein, Хусейн Али, Christopher D. Tristan, Тристан Кристофер Д.

    One of the serious and rare complications of Intrauterine Contraceptive Device (IUCD) migration is intravesical stone formation. This report presents a case of a large bladder calculus secondary to a migrated IUCD, highlighting the clinical presentation, diagnostic challenges, and subsequent surgical management. We report the case of a 41-year-old multiparous woman with a history of long-term IUCD use, presenting with a four-month history of chronic lower abdominal pain, dysuria, urinary frequency, urgency, incomplete bladder emptying, and straining to void. Abdominal radiography revealed a large bladder calculus with a central nidus suggestive of a forgotten and migrated IUCD. The patient's contraceptive history included multiple IUCD insertions between 2009 and 2022. The patient underwent open vesicolithotomy under regional anesthesia. Intraoperatively, a bladder stone measuring 4.7 × 4.0 cm encasing an IUCD was successfully removed. Three months postoperatively, the patient's lower urinary tract symptoms had resolved, demonstrating significant clinical improvement. Clinical awareness of this rare complication enhance early detection and facilitate appropriate management to prevent long-term complications.

  • Feasibility of pulsed field ablation for ventricular arrhythmia: a systematic review

    by Irnizarifka Irnizarifka, Christopher Daniel Tristan, Enrico Ananda Budiono, Matthew Aldo Wijayanto, Immanuel Soni Tanudjaya, Raymond Pranata, Mohammad Iqbal

    Beyond its efficacy on atrial fibrillation, pulsed field ablation (PFA) presents potential advantages in ventricular arrhythmia. This study sought to investigate the feasibility of PFA for ventricular tachycardia (VT) and premature ventricular complexes (PVC). A systematic search (Scopus, PubMed, and Science Direct) with citation searching was performed on 9 January 2026. Studies evaluating the feasibility of PFA in VT and PVC were included. This study included seven studies (74 patients with VT and 86 with PVC). Pooled acute procedural success rate in VT was 0.92 (95% CI: 0.86-0.99) and in the PVC was 0.93 (95% CI: 0.86-1.00). During follow-up, VT recurrence rates ranged from 20% to 54%. PVC ablation demonstrated a significant burden reduction (MD: 86.54%; 95% CI: 59.21-113.86; p = 0.005) with long-term success rates ranging from 50% to 85%. Safety evaluation demonstrated satisfactory outcomes, with major adverse cardiovascular events (MACE) during follow-up occurring in four patients with high-risk comorbidity. Major adverse events (AEs) occurred in 11 patients and were preventable; minor AEs consisted solely of vascular access site AEs. PFA was feasible for VT and PVC ablation. Larger long-term studies and standardized protocol were urgently necessary to ensure efficacy with minimal AEs. www.crd.york.ac.uk/prospero identifier is CRD420251272352.


  • Open Access

    Catheter-directed thrombolysis versus anticoagulation for intermediate-risk and high-risk pulmonary embolism: a systematic review and meta-analysis

    by Artha Maressa Simanjuntak, Frengki Prabowo Wijayanto, Christopher Daniel Tristan, Matthew Aldo Wijayanto, Muhammad Reva Aditya, Garnis Latifah Hasturani, Antonio Anna Lukito, Raymond Pranata

    Background: Catheter-directed thrombolysis (CDT) has emerged as a reperfusion strategy for intermediate-risk and high-risk pulmonary embolism (PE), potentially improving thrombus resolution while reducing bleeding risk compared with systemic thrombolysis. However, evidence comparing CDT with anticoagulation alone remains inconsistent. Objective: To evaluate the efficacy and safety of CDT compared with anticoagulation alone in intermediate-risk and high-risk PE. Methods: A systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, Scopus, Cochrane Library, Epistemonikos and ProQuest were searched through 8 May 2026. Randomised and observational studies comparing CDT with anticoagulation alone were included. Primary outcomes were all-cause mortality and major bleeding. Random-effects models were used to calculate pooled risk ratios (RRs) and mean differences with 95% CIs. Results: 18 studies involving 16 126 patients were included. CDT was associated with a lower risk of all-cause mortality compared with anticoagulation alone (RR 0.41, 95% CI 0.32 to 0.54; p<0.0001; I²=0%). No statistically significant difference was observed in major bleeding (RR 1.78, 95% CI 0.85 to 3.71; p=0.1259; I²=51.3%), and trim-and-fill analysis yielded a similarly non-significant result (adjusted RR 0.84, 95% CI 0.39 to 1.79). CDT and anticoagulation alone showed comparable outcomes for PE-related mortality, intracranial haemorrhage, delta right ventricle (RV)/left ventricle (LV) ratio, delta Thrombus Burden Score or systolic pulmonary artery pressure. Meta-regression identified that a greater baseline RV/LV ratio was associated with attenuation of the observed mortality benefit. Conclusions: CDT was associated with lower all-cause mortality compared with anticoagulant alone in intermediate-risk and high-risk PE without a statistically significant increase in intracranial haemorrhage. Larger adequately powered randomised trials are needed to define the role of CDT in acute PE. PROSPERO registration number: CRD420261373193.


  • Pacing‐Induced Cardiomyopathy in Leadless and Transvenous Pacemakers: A Meta‐Analysis and Meta‐Regression

    by Frengki Prabowo Saputro Wijayanto, Artha Maressa Theodora Simanjuntak, Christopher Daniel Tristan, Alberta Claudia Undarsa, Antonia Anna Lukito, Raymond Pranata

    Background: Leadless pacemakers have been developed to reduce complications associated with transvenous systems; however, their impact on pacing‐induced cardiomyopathy (PICM) remains uncertain. This study aimed to evaluate the prevalence of PICM following leadless pacing, compared PICM risk with transvenous pacing, and assessed cardiac resynchronization therapy (CRT) upgrade. Methods: This systematic review and meta‐analysis followed PRISMA guidelines. PubMed, Scopus, and ScienceDirect were searched up to January 2026. Studies reporting PICM following leadless pacing or comparing leadless and transvenous systems were included. Random‐effects models estimated pooled prevalence and risk ratios (RRs), and meta‐regression explored potential modifiers. Results: Eight studies comprising 3224 patients with leadless pacing were included. The pooled prevalence of PICM following leadless pacing was 13% (95%CI: 4%–23%; I 2 = 92%). In comparative analysis (5 studies; n = 6025), the risk of PICM was similar between leadless and transvenous pacing (RR 1.00; 95%CI: 0.77–1.29; I 2 = 52%). Leadless pacing was associated with a lower observed rate of CRT upgrade (RR 0.56; 95%CI: 0.48–0.66; I 2 = 42%), although this finding should be interpreted cautiously because it may reflect patient selection, procedural factors, and differing thresholds for CRT upgrade. Meta‐regression identified baseline heart failure (HF) as a significant predictor of PICM ( p < 0.0001). Conclusion: Leadless pacemakers demonstrate a non‐inferior risk of PICM and similar safety profiles to transvenous systems, while a lower observed rate of CRT upgrade. Future studies should standardize PICM definitions and improve reporting of pacing burden, ventricular function, and patient‐level outcomes.